A role for an HTLV-1 vaccine?
HTLV-1 is a global infection with 5-20 million infected individuals. Although only a minority of infected individuals develop myelopathy, lymphoproliferative malignancy, or inflammatory disorders, infection is associated with immunosuppression and shorter survival. Transmission of HTLV-1 is through...
Main Author: | Lee Ratner |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.953650/full |
Similar Items
-
A protective role of HTLV-1 gp46-specific neutralizing and antibody-dependent cellular cytotoxicity-inducing antibodies in progression to adult T-cell leukemia (ATL)
by: Yuetsu Tanaka, et al.
Published: (2022-09-01) -
Conservation of a Neutralization Epitope of Human T-cell Leukemia Virus Type 1 (HTLV-1) among Currently Endemic Clinical Isolates in Okinawa, Japan
by: Mariko Mizuguchi, et al.
Published: (2020-01-01) -
Tuning Rex rules HTLV-1 pathogenesis
by: Kazumi Nakano, et al.
Published: (2022-09-01) -
Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies
by: Niloofar Seighali, et al.
Published: (2023-05-01) -
The MHC-II Transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators
by: Greta eForlani, et al.
Published: (2013-08-01)